6.
Fraser E
. Long term respiratory complications of covid-19. BMJ. 2020; 370:m3001.
DOI: 10.1136/bmj.m3001.
View
7.
Ferguson N, Galvani A, Bush R
. Ecological and immunological determinants of influenza evolution. Nature. 2003; 422(6930):428-33.
DOI: 10.1038/nature01509.
View
8.
Kallen K, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A
. A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. Hum Vaccin Immunother. 2013; 9(10):2263-76.
PMC: 3906413.
DOI: 10.4161/hv.25181.
View
9.
Kim H, Cha H, Cheong T
. Analyzing economic effect on mRNA vaccine inventory management with redistribution policy. Sci Rep. 2024; 14(1):20425.
PMC: 11371817.
DOI: 10.1038/s41598-024-71322-5.
View
10.
Lyons D, Lauring A
. Mutation and Epistasis in Influenza Virus Evolution. Viruses. 2018; 10(8).
PMC: 6115771.
DOI: 10.3390/v10080407.
View
11.
Uversky V, Redwan E, Makis W, Rubio-Casillas A
. IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein. Vaccines (Basel). 2023; 11(5).
PMC: 10222767.
DOI: 10.3390/vaccines11050991.
View
12.
Nam M, Yun S, Kim S, Kim C, Cha J, Lee C
. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses. Microbiol Spectr. 2022; 10(4):e0249521.
PMC: 9431224.
DOI: 10.1128/spectrum.02495-21.
View
13.
Klein N, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson K
. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021; 326(14):1390-1399.
PMC: 8511971.
DOI: 10.1001/jama.2021.15072.
View
14.
Adams M, Lefkowitz E, King A, Harrach B, Harrison R, Knowles N
. Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2017). Arch Virol. 2017; 162(8):2505-2538.
DOI: 10.1007/s00705-017-3358-5.
View
15.
Koutsakos M, Wheatley A, Laurie K, Kent S, Rockman S
. Influenza lineage extinction during the COVID-19 pandemic?. Nat Rev Microbiol. 2021; 19(12):741-742.
PMC: 8477979.
DOI: 10.1038/s41579-021-00642-4.
View
16.
Lee Y, Jeong M, Park J, Jung H, Lee H
. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp Mol Med. 2023; 55(10):2085-2096.
PMC: 10618257.
DOI: 10.1038/s12276-023-01086-x.
View
17.
Dos Reis M, Tamuri A, Hay A, Goldstein R
. Charting the host adaptation of influenza viruses. Mol Biol Evol. 2010; 28(6):1755-67.
PMC: 3098510.
DOI: 10.1093/molbev/msq317.
View
18.
Tadic S, Martinez A
. Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer?. Front Immunol. 2024; 15:1433185.
PMC: 11286457.
DOI: 10.3389/fimmu.2024.1433185.
View
19.
Mahanty S, Prigent A, Garraud O
. Immunogenicity of infectious pathogens and vaccine antigens. BMC Immunol. 2015; 16:31.
PMC: 4446803.
DOI: 10.1186/s12865-015-0095-y.
View
20.
Clemente B, Denis M, Silveira C, Schiavetti F, Brazzoli M, Stranges D
. Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design. Front Immunol. 2023; 14:1294929.
PMC: 10711611.
DOI: 10.3389/fimmu.2023.1294929.
View